Department of Cardiology II-Electrophysiology, University Hospital Münster, Munster, Germany.
Clin Res Cardiol. 2019 Jan;108(1):16-21. doi: 10.1007/s00392-018-1296-1. Epub 2018 Jun 12.
The subcutaneous ICD is a promising treatment option in patients at risk for sudden cardiac death. Approved in 2009, the first S-ICD in Germany was implanted in June 2010. Although large prospective registry studies have shown safety and efficacy of the system, there is a lack of long-term data with regard to battery longevity of the S-ICD. Therefore, we report follow-up of our first initial S-ICD cases from implantation till battery depletion.
All S-ICD patients with device replacement for battery depletion in our large single-center S-ICD registry were included in this study. Baseline characteristics, appropriate and inappropriate shocks, and complications were documented in a median follow-up of 75.9 ± 6.8 months.
Twenty-eight patients with S-ICD systems were included in this study. Of these patients, 21 were male and 7 were female, with an overall mean age of 41.9 ± 12.6 years. Primary prevention of sudden cardiac death was the indication in 19 patients (67.9%). Ventricular tachycardia was adequately terminated in two patients (7.1%). In 7 patients, non-sustained ventricular arrhythmias were not treated. A total of three inappropriate shocks occurred in three patients (10.7%). Mean time from implantation till battery depletion was 65.8 ± 8.1 months. Only one patient presented premature elective replacement criteria because of rapid battery depletion. No lead-related complication occurred during follow-up and no complications were seen regarding device replacement. In one patient (3.6%), the system was explanted without replacement due to patient's preference.
The estimated battery longevity of S-ICD of about 5 years was reached in all but one patient. Compared to larger S-ICD registry studies, frequency of inappropriate shocks was relatively high in the initial S-ICD cases. Both technological improvement as well as programming and operators' experience have led to a reduction of complications. Replacement of the S-ICD seems to be a safe and effective procedure.
皮下 ICD 是一种有前途的治疗方法,适用于有心脏性猝死风险的患者。该设备于 2009 年获得批准,德国首例 S-ICD 于 2010 年 6 月植入。尽管大型前瞻性注册研究表明该系统具有安全性和有效性,但缺乏有关 S-ICD 电池寿命的长期数据。因此,我们报告了我们首例初始 S-ICD 病例从植入到电池耗尽的随访情况。
我们的大型单中心 S-ICD 注册中心中,所有因电池耗尽而更换设备的 S-ICD 患者均被纳入本研究。在中位数随访 75.9±6.8 个月时,记录了患者的基线特征、适当和不适当的电击以及并发症。
本研究共纳入 28 例 S-ICD 系统患者。其中 21 例为男性,7 例为女性,平均年龄为 41.9±12.6 岁。19 例患者(67.9%)的适应证为预防心脏性猝死。2 例患者(7.1%)成功终止了室性心动过速。7 例患者未治疗非持续性室性心律失常。3 例患者共发生 3 次不适当电击(10.7%)。从植入到电池耗尽的平均时间为 65.8±8.1 个月。仅 1 例患者因电池快速耗尽而提前出现选择性更换标准。在随访期间,没有发生与导联相关的并发症,也没有发生与设备更换相关的并发症。1 例患者(3.6%)因患者偏好而未更换设备而将系统取出。
除 1 例患者外,所有患者的 S-ICD 电池估计寿命都达到了 5 年左右。与更大的 S-ICD 注册研究相比,初始 S-ICD 病例的不适当电击频率相对较高。技术改进、编程和操作人员经验的提高都导致了并发症的减少。S-ICD 的更换似乎是一种安全有效的方法。